171 results
8-K
EX-99.1
BCLI
Brainstorm Cell Therapeutics, Inc.
16 Apr 24
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
9:31pm
) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 trial in ALS (NCT03280056); this trial investigated the safety
8-K
EX-99.1
BCLI
Brainstorm Cell Therapeutics, Inc.
11 Apr 24
Other Events
6:10am
); this trial investigated the safety and efficacy of repeat administration of autologous MSC-NTF cells and was supported by a grant from the California Institute
8-K
EX-99.1
BCLI
Brainstorm Cell Therapeutics, Inc.
9 Apr 24
BrainStorm Cell Therapeutics Announces Agreement with FDA on a
6:05am
designed to evaluate the effectiveness and safety of NurOwn. This trial builds on valuable insights from our earlier studies and will enroll people … trial (Study BCT-006-US) will be a two-part, multicenter, study designed to assess the efficacy and safety of NurOwn in patients with ALS. The entry
8-K
EX-99.1
BCLI
Brainstorm Cell Therapeutics, Inc.
1 Apr 24
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
8:15am
. The design is for a two-part, multicenter, Phase 3b study to assess the efficacy and safety of NurOwn in participants with ALS, earlier in the disease … lateral sclerosis (ALS). BrainStorm has completed a Phase 3 trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat
8-K
EX-99.1
v0ckj
20 Dec 23
BrainStorm Issues 2023 Letter to Shareholders
5:04pm
8-K
EX-99.1
oac3vdd k1vb
22 Nov 23
BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALS
6:03am
8-K
EX-99.1
rz0pknrw gyfnhg
14 Nov 23
BrainStorm Cell Therapeutics Announces Third quarter 2023 Financial Results and Provides Corporate Update
12:00am
8-K
EX-99.1
8xehzotx44b3vxbwa
24 Oct 23
BrainStorm Cell Therapeutics Announces Strategic Realignment
7:30am
8-K
EX-99.1
qz64nicvjqd8zfecznd9
14 Aug 23
BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
7:21am
8-K
EX-10.1
1tvmc
19 Jul 23
Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering
4:05pm
8-K
EX-99.1
nd4xobpgo3veszbd0qg6
19 Jul 23
Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering
4:05pm
8-K
EX-99.1
r5u4q n2gjnd8
20 Jun 23
BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair
5:01pm
8-K
EX-99.1
1xc3j2id
6 Jun 23
Regulation FD Disclosure
8:58am
8-K
EX-99.1
hapjv j3bzc
15 May 23
BrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
7:15am
8-K
EX-99.1
urb449mfjinw
30 Mar 23
BrainStorm Cell Therapeutics Announces Full Year 2022 Financial Results and Provides a Corporate Update
7:18am